People · Operator
Named in public records as an officer, director or promoter · active 2017–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Rubius Therapeutics, Inc. | — | Biotechnology | Series D+ | $216.2M | $4.2B | 2017 |
Michael Barton Rosenblatt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Barton Rosenblatt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert S Langer | 1 | 14 |
| Peter Barton Hutt | 1 | 14 |
| Noubar B Afeyan | 1 | 5 |
| Christopher L. Carpenter | 1 | 1 |
| Torben Straight Nissen | 1 | 1 |
| Francis B. Cuss | 1 | 1 |
| Catherine B. Sohn | 1 | 1 |
| Michael S. Rosenblatt | 1 | 1 |
| Roger S. Pomerantz | 1 | 1 |
| Joanne Protano | 1 | 1 |
| David Straight Epstein | 1 | 1 |
| Andrew B. Oh | 1 | 1 |
| Harvey F. Lodish | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.